InsiderSignal.AI

InsiderSignal.ai

ANNX - Annexon, Inc.

Insider Sale by Yednock Ted (EVP, CHIEF INNOVATION OFFICER)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Yednock Ted, serving as EVP, CHIEF INNOVATION OFFICER at Annexon, Inc. (ANNX), sold 5,566 shares at $5.42 per share, for a total transaction value of $30,168.00. Following this transaction, Yednock Ted now holds 154,161 shares of ANNX.

This sale represents a 3.00% decrease in Yednock Ted's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Monday, March 2, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, March 4, 2026, 2 days after the trade was made.

Annexon, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Yednock Ted

Yednock Ted

EVP, CHIEF INNOVATION OFFICER

Ted Yednock, Ph.D. is an accomplished biopharmaceutical executive serving as Executive Vice President and Chief Innovation Officer at Annexon, Inc. (ANNX) since October 2021, and Chair of the Scientific Advisory Board since November 2023. He previously held the role of EVP and Chief Scientific Officer at Annexon from 2013 to October 2021, where he built R&D leadership and advanced programs in neuroinflammatory and autoimmune diseases.[[1]](https://fintool.com/app/research/companies/ANNX/people/ted-yednock)[[4]](https://annexonbio.com/team/ted-yednock-phd/) Dr. Yednock earned a B.S. in Biology and Chemistry from the University of Illinois in 1979 and a Ph.D. in Anatomy and Cell Biology from the University of California, San Francisco in 1986.[[1]](https://fintool.com/app/research/companies/ANNX/people/ted-yednock)[[2]](https://www.marketscreener.com/insider/TED-YEDNOCK-A0RX6R/) His career highlights include serving as Chief Scientific Officer at Prothena Corporation, Head of Global Research at Elan Pharmaceuticals (1996–2013), and Scientist at Athena Neurosciences (1990–1996), where he was the scientific inventor of Tysabri (natalizumab) for multiple sclerosis.[[1]](https://fintool.com/app/research/companies/ANNX/people/ted-yednock)[[2]](https://www.marketscreener.com/insider/TED-YEDNOCK-A0RX6R/)[[4]](https://annexonbio.com/team/ted-yednock-phd/) He has made significant contributions to therapies for Alzheimer’s, Parkinson’s, amyloidosis, rheumatoid arthritis, psoriasis, and Crohn’s disease, and recently engaged in insider trading activities at Annexon, including share sales and equity awards.[[1]](https://fintool.com/app/research/companies/ANNX/people/ted-yednock)[[3]](https://www.gurufocus.com/insider/131233/ted-yednock)[[6]](https://www.tipranks.com/news/insider-trading/annexon-leadership-makes-bold-move-with-coordinated-stock-sales-insider-trading-news)[[8]](https://www.investing.com/news/insider-trading-news/annexon-evp-yednock-sells-29k-in-shares-93CH-4138446)

View full insider profile →

Trade Price

$5.42

Quantity

5,566

Total Value

$30,168.00

Shares Owned

154,161

Trade Date

Monday, March 2, 2026

3 days ago

SEC Filing Date

Wednesday, March 4, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Annexon, Inc.

Company Overview

No company information available
View news mentioning ANNX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4496971

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime